Proactive团队报道 - Emily Jarvie在澳大利亚和加拿大从事政治新闻和商业报道[1] - Proactive的新闻团队遍布全球金融和投资中心[2] Proactive团队关注领域 - Proactive团队专注于中小市值市场和蓝筹公司等投资故事[3] - Proactive团队涵盖生物技术、矿业、能源、数字货币和新兴技术等领域[4]

The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run? Vertex Pharmaceuticals (VRTX -1.71%) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now hitting the $100 billion mark, has it become too expensive of an investment? Is it time for investors to consider other stocks instead, or can Vertex still be a good buy right now? Let's dive in and take a look. Why inves ...

股价表现 - Vertex Pharmaceuticals (VRTX) 最新收盘价为$397.58，较前一天下跌了1.71%[1] 财报预测 - Vertex Pharmaceuticals计划于2024年5月6日公布财报，预计每股收益将增长33.44%[3] - Zacks Consensus Estimates预测Vertex Pharmaceuticals整个财年的每股收益为$16.79，营收为106.9亿美元[4]

This innovative machine rolls on. Biotech giant Vertex Pharmaceuticals (VRTX -0.82%) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive phase 3 results for exciting candidates. The drugmaker isn't stopping. Vertex is moving forward with another investigational medicine that could become a big deal somewhere down the road. Let's find out what it is and what it could mean for investors. Straight out of the playbook Firs ...

Vertex Pharmaceuticals (VRTX) initiated the late-stage portion of the phase II/III AMPLITUDE study evaluating inaxaplin (VX-147) in APOL1-mediated kidney disease (AMKD), a genetic disorder affecting kidney function. This phase III portion will evaluate a 45 mg oral dose of Vertex’s drug, on top of standard of care, in AMKD patients, compared with placebo. Management also expanded the study to include adolescents aged 10 and older with AMKD. Previously, the AMPLITUDE study only enrolled adults with the disea ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $420.48, with a +0.59% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.2%. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%. Prior to today's trading, shares of the drugmaker had lost 3.41% over the past month. This has lagged the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time. The investment community will be ...

Biotech giant Vertex Pharmaceuticals (VRTX 0.17%) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while displaying its incredible innovative abilities. Thankfully, it's not too late to invest in Vertex even with the market-beating returns it has provided in recent years. The company's underlying business remains as strong as ever -- strong enough that the stock is an excellent "forever" pick. Let's find out more. ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has cleared its investigational new drug application to begin clinical development of its pipeline candidate, VX-407, for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Vertex plans to begin a phase I study on VX-407 in ADPKD later this month. VX-407 is a first-in-class small molecule corrector that targets the underlying cause of this common inherited kidney disease, which leads to growth of several kidney-enlarging c ...

Solskin/DigitalVision via Getty Images Vertex Pharmaceuticals (NASDAQ:VRTX) is a promising biotechnology with solid financial results in 2023, a dominant Cystic fibrosis ("CF") franchise, and is on track to diversify its drug portfolio by launching five new products by 2028, which include its newest CF drug, a non-opioid pain management drug, and a therapy addressing Sickle Cell Disease and Beta-Thalassemia. Several of these solutions have the potential to produce blockbuster status. Investors were excited ...

股价表现 - Vertex Pharmaceuticals (VRTX) 最近的股价为 $411.38，较前一个交易日收盘价上涨了0.91% [1] - Vertex Pharmaceuticals 过去一个月的股价下跌了3.44%，落后于医药行业的涨幅0.91%和标普500指数的涨幅1.76% [2] 盈利预期 - 预计 Vertex Pharmaceuticals 的季度盈利每股为 $4.07，同比增长33.44%，营收预期为 $2.55 亿美元，同比增长7.34% [3] - Zacks Consensus Estimates 预测 Vertex Pharmaceuticals 整个财年的盈利为每股 $16.79，营收为 $106.9 亿美元，分别较去年增长了10.24%和8.27% [4] 分析师预测 - 投资者应关注分析师对 Vertex Pharmaceuticals 的最新预测变化，这些调整通常反映了短期业务模式的变化 [5] - 研究表明，这些预测变化与即将到来的股价表现有直接关联，Zacks Rank 利用这一现象开发了一个清晰的可操作评级模型 [6] 行业比较 - Vertex Pharmaceuticals 目前的 Forward P/E 比率为 24.28，高于行业平均值 24.2 [8] - VRTX 的 PEG 比率为 1.98，略高于医疗 - 生物医学和遗传学行业的平均 PEG 比率 1.58 [9] 行业排名 - 医疗 - 生物医学和遗传学行业是医疗行业的一部分，目前的 Zacks Industry Rank 为 71，在所有行业中排名前 29% [10] - Zacks Industry Rank 通过计算各个股票的平均 Zacks Rank 来评估各行业群体的实力，研究显示排名前50%的行业的表现是排名后50%的两倍 [11]